Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted therapy using alpha emitters

G Vaidyanathan1, M R Zalutsky

  • 1Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA.

Physics in Medicine and Biology
|October 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies.

Bioorganic & medicinal chemistry·2012
Same author

A case of curative-intent hepatectomy for colon cancer metastatic to the scapula and liver.

Anticancer research·2010
Same author

Meta-iodobenzylguanidine and analogues: chemistry and biology.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2008
Same author

TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.

Oncogene·2008
Same author

Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211At via a tin precursor.

Bioconjugate chemistry·2006
Same author

Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·2005
Same journal

Effective contrast-enhanced preprocessing for intracranial artery segmentation in digital subtraction angiography.

Physics in medicine and biology·2026
Same journal

Improving Plan Quality in Adaptive Proton Therapy Using an Interactive Dose Modification Tool.

Physics in medicine and biology·2026
Same journal

Technical Note: Real-Time MLC Control and Latency Measurement Optimization with External Verification.

Physics in medicine and biology·2026
Same journal

Fetus-Specific Hematopoietic Stem Cell Dosimetry Framework for Leukemia-Relevant Target Cells During Prenatal Development.

Physics in medicine and biology·2026
Same journal

Deep learning-based dose prediction to enhance planning efficiency in cervical brachytherapy with hybrid applicators.

Physics in medicine and biology·2026
Same journal

Corrigendum: Referenceless MR thermometry-a comparison of five methods (2017<i>Phys. Med. Biol</i>.<b>62</b>1-16).

Physics in medicine and biology·2026
See all related articles

Alpha-particle emitting radionuclides like Astatine-211 (211At) show promise for targeted radiotherapy. Meta-[211At] astatobenzylguanidine demonstrates high toxicity against neuroblastoma cells, suggesting potential for treating micrometastases.

Area of Science:

  • Nuclear medicine
  • Radiopharmaceutical chemistry
  • Oncology

Background:

  • Alpha-particle emitting radionuclides offer targeted radiotherapy due to short tissue penetration and high biological effectiveness.
  • Traditional beta-particle emitters have longer ranges and lower linear energy transfer.
  • Various delivery methods for alpha-emitters like 211At and 212Bi are under investigation.

Purpose of the Study:

  • To evaluate the potential of meta-[211At] astatobenzylguanidine as an alpha-emitting radiopharmaceutical for targeted cancer therapy.
  • To compare the efficacy of meta-[211At] astatobenzylguanidine with its iodine-131 labeled counterpart.

Main Methods:

  • Utilized [3H]thymidine incorporation assays to assess cell toxicity.
  • Employed limiting dilution clonogenic assays to determine cell survival.

Related Experiment Videos

  • Quantified the number of 211At atoms bound per cell required to inhibit colony formation.

    • Main Results:

    • Meta-[211At] astatobenzylguanidine exhibited approximately 1000-fold higher toxicity than meta-[131I] iodobenzylguanidine against human neuroblastoma cells.
    • A low dose of 6-7 atoms of 211At per cell was sufficient to inhibit colony formation.
    • Demonstrated significant cell-killing potential at the single-cell level.

    Conclusions:

    • Meta-[211At] astatobenzylguanidine is a highly potent radiopharmaceutical agent.
    • Its efficacy suggests potential for treating micrometastatic neuroblastomas.
    • Further research into alpha-emitting radiopharmaceuticals is warranted for targeted cancer treatment.